The use of vitamin D in endometriosis treatment
DOI: 10.32364/2618-8430-2023-6-2-126-129
E.Yu. Dobrokhotova1, A.V. Sofronov2
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2N.I. Pirogov City Clinical Hospital No. 1, Moscow, Russian Federation
The article reviews the literature on the use of vitamin D in endometriosis treatment. Endometriosis, one of the most common health problems in the female population, is an estrogen-dependent chronic inflammatory disease. Endometriosis affects 10-15% of all women of reproductive age and 35–50% of women with chronic pelvic pain and/or infertility. Despite multiple studies in all aspects of endometriosis, the selection of the most effective individualized combination treatment options for each patient is still considered as a pressing issue. Animal experiments and clinical trials have demonstrated multiple immune system changes in endometriosis occurring at different levels, from aberrant cytokine signaling to alterations of the immune system cell populations. There is a growing number of recent reports in the international and domestic literature describing the impact of vitamin D on the clinical course of endometriosis and the options of its use in this disease. There is a pathogenetic rationale for involving vitamin D in combination therapy of endometriosis in view of its immunomodulatory, anti-proliferative and anti-angiogenic properties. However, it is suggested that further studies are needed to determine an optimum therapeutic dose of vitamin D for different endometriosis types.
Keywords: vitamin D, colecalciferol, calcitriol, endometriosis, ectopic endometrium, vitamin D deficiency.
For citation: Dobrokhotova E.Yu., Sofronov A.V. The use of vitamin D in endometriosis treatment. Russian Journal of Woman and Child Health. 2023;6(2):126–129 (in Russ.). DOI: 10.32364/2618-8430-2023-6-2-126-129.
About the authors:
Yuliya E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7830-2290.
Aleksey V. Sofronov — obstetrician and gynecologist, N.I. Pirogov City Clinical Hospital No. 1; 8, Leninskiy av., Moscow, 117049, Russian Federation; ORCID iD 0009-0008-3956-9743.
Contact information: Aleksey V. Sofronov, e-mail: saf595959@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 06.03.2023.
Revised 30.03.2023.
Accepted 24.04.2023.
4. Доброхотова Ю.Э., Калиматова Д.М. Влияние витамина D на эндометриоз. Фарматека. 2018;6(359):84–88. [Dobrokhotova Yu.E., Kalimatova D.M. Vitamin D influence on endometriosis. Farmateka. 2018;6(359):84–88 (in Russ.)].
5. Ярмолинская М.И., Денисова В.М. Иммуномодулирующая терапия генитального эндометриоза: реалии и перспективы применения. Фарматека. 2015;12(305):6–12. [Yarmolinskaya M.I., Denisova B.M. Immunomodulatory therapy for genital endometriosis: realities and prospects for application. Farmateka. 2015;12(305):6–12 (in Russ.)].
6. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Ross A.C., Taylor C.L., Yaktine A.L., Del Valle H.B., eds. Washington (DC): National Academies Press (US); 2011. DOI: 10.17226/13050.
7. Christakos S., Barletta F., Huening M. et al. Vitamin D target proteins: function and regulation. J Cell Biochem. 2003;88(2):238–244. DOI: 10.1002/jcb.10349.
8. Kinuta K., Tanaka H., Moriwake T. et al. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology. 2000;141(4):1317–1324. DOI: 10.1012/endo.141.4.7403.
9. Grundmann M., von Versen-Höynck F. Vitamin D - roles in women's reproductive health? Reprod Biol Endocrinol. 2011;9:146. DOI: 10.1186/1477-7827-9-146.
10. Norman A.W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006;147(12):5542–5548. DOI: 10.1210/en.2006-0946.
11. Nandi A., Sinha N., Ong E. et al. Is there a role for vitamin D in human reproduction? Horm Mol Biol Clin Investig. 2016;25(1):15–28. DOI: 10.1515/hmbci-2015-0051.
12. Bodnar L.M., Simhan H.N., Powers R.W. et al. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr. 2007;137(2):447–452. DOI: 10.1093/jn/137.2.447.
13. Kotsa K., Yavropoulou M.P., Anastasiou O. et al. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009;92(3):1053–1058. DOI: 10.1016/j.fertnstert.2008.07.1757.
14. Kalaitzopoulos D.R., Lempesis I.G., Athanasaki F. et al. Association between vitamin D and endometriosis: a systematic review. Hormones (Athens). 2020;19(2):109–121. DOI: 10.1007/s42000-019-00166-w. 15. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 2002;8(4):174–179. DOI: 10.1016/s1471-4914(02)02294-3.
16. Mariani M., Viganò P., Gentilini D. et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012;27(7):2010–2019. DOI: 10.1093/humrep/des150.
17. Abbas M.A., Taha M.O., Disi A.M., Shomaf M. Regression of endometrial implants treated with vitamin D3 in a rat model of endometriosis. Eur J Pharmacol. 2013;715(1-3):72–75. DOI: 10.1016/j.ejphar.2013.06.016.
18. Yildirim B., Guler T., Akbulut M. et al. 1-alpha,25-dihydroxyvitamin D3 regresses endometriotic implants in rats by inhibiting neovascularization and altering regulation of matrix metalloproteinase. Postgrad Med. 2014;126(1):104–110. DOI: 10.3810/pgm.2014.01.2730. 19. Ярмолинская М.И., Денисова А.С., Андреева Н.Ю. Эффективность применения витамина D (колекальциферола) в терапии хирургически индуцированного эндометриоза у крыс. Российский вестник акушера-гинеколога. 2019;19(3):37–42. DOI: 10.17116/rosakush20191903137. [Yarmolinskaya M.I., Denisova A.S., Andreeva N.Yu. The effectiveness of vitamin D3 (cholecalciferol) in the treatment of surgically induced endometriosis in rats. Russian Bulletin of obstetrician-gynecologist. 2019;19(3):37–42 (in Russ.)]. DOI: 10.17116/rosakush20191903137. 20. Delbandi A.A., Mahmoudi M., Shervin A., Zarnani A.H. 1,25-Dihydroxy Vitamin D3 Modulates Endometriosis-Related Features of Human Endometriotic Stromal Cells. Am J Reprod Immunol. 2016;75(4):461–473. DOI: 10.1111/aji.12463.
21. Miyashita M., Koga K., Izumi G. et al. Effects of 1,25-Dihydroxy Vitamin D3 on Endometriosis. J Clin Endocrinol Metab. 2016;101(6):2371–2379. DOI: 10.1210/jc.2016-1515.
22. Ingles S.A., Wu L., Liu B.T. et al. Differential gene expression by 1,25(OH)2D3 in an endometriosis stromal cell line. J Steroid Biochem Mol Biol. 2017;173:223–227. DOI: 10.1016/j.jsbmb.2017.01.011.
23. Qiu Y., Yuan S., Wang H. Vitamin D status in endometriosis: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020;302(1):141–152. DOI: 10.1007/s00404-020-05576-5. 24. Faserl K., Golderer G., Kremser L. et al. Polymorphism in vitamin D-binding protein as a genetic risk factor in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2011;96(1):E233–E241. DOI: 10.1210/jc.2010-1532.
25. Yamamoto N., Naraparaju V.R. Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats. Cell Immunol. 1996;170(2):161–167. DOI: 10.1006/cimm.1996.0148. 26. Binder R., Kress A., Kan G. et al. Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol Immunol. 1999;36(13-14):885–892. DOI: 10.1016/s0161-5890(99)00110-8. 27. Kalu E., Sumar N., Giannopoulos T. et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. J Obstet Gynaecol Res. 2007;33(4):490–495. DOI: 10.1111/j.1447-0756.2007.00569.x. 28. Ахмедова С.Р., Омаров Н.С. Показатели цитокинового баланса и сосудисто-эпителиального фактора роста в зависимости от уровня витамина D у пациенток с наружным генитальным эндометриозом. Медицинский алфавит. 2020;4:55–58. DOI: 10.33667/2078-5631-2020-4-55-58. [Akhmedova S.R., Omarov N.S. Parameters of cytokine balance and vascular-epithelial growth factor depending on level of vitamin D in patients with external genital endometriosis. Medical alphabet. 2020;4:55–58 (in Russ.)]. DOI: 10.33667/2078-5631-2020-4-55-58.
29. Оразов М.Р., Хамошина М.Б., Носенко Е.Н. и др. Роль витамина D в патогенезе тазовой боли, обусловленной наружным генитальным эндометриозом. Доктор.Ру. 2019;7(162):36–39. DOI: 10.31550/1727-2378-2019-162-7-36-39. [Orazov M.R., Khamoshina M.B., Nosenko E.N. et al. The Pathogenic Role of Vitamin D in Pelvic Pain Associated with External Genital Endometriosis. Doctor.Ru. 2019;7(162):36–39 (in Russ.)]. DOI: 10.31550/1727-2378-2019- 162-7-36-39.
30. Mehdizadehkashi A., Rokhgireh S., Tahermanesh K. et al. The effect of vitamin D supplementation on clinical symptoms and metabolic profiles in patients with endometriosis. Gynecol Endocrinol. 2021;37(7):640–645. DOI: 10.1080/09513590.2021.1878138.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать